Pfizer Inc. (NYSE:PFE) is one of the best growth stocks under $50 to buy now. On September 8, Pfizer Inc. (NYSE:PFE) and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort “evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19.”
Management reported that the preliminary data exhibited considerable growth in neutralizing antibodies targeting the LP.8.1 sublineage of SARS-CoV-2 after the vaccination, reinforcing pre-clinical data that supported the recent U.S. Food and Drug Administration (FDA) approval of the LP.8.1-adapted COVID-19 vaccine demonstrating improved immune responses against multiple circulating SARS-CoV-2 sublineages.
Pfizer Inc. also reported that the vaccine’s safety profile was consistent with previous studies, and no new safety concerns were identified.
Pfizer Inc. is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
